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ABSTRACT 
 
This thesis concerns the synthesis and biological evaluation of microtubules (MT) inhibitors of the 
type 2-aryl-1,4-naphthoquinone-1-oxime methyl ether. 
 
Following a comprehensive review on MT and MT targeting drugs, the first part of the Results and 
Discussion section (Chapter 2) of the thesis, a library of derivatives of 2-aryl-subtituted (Chapter 3) 
are described and evaluated for their inhibitory activity against tubulin in Hela cell culture. 
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ABBREVIATIONS 
 
 
AcOH    Acetic acid 
aq.    Aqueous 
Ar    Aromatic 
BnBr                  Benzyl bromide 
Boc                  tert-Butyl carbonate 
BOP           Benzotriazol-1-yloxy-tris(dimethylamino) 
Phosphonium  hexafluoro phosphate 
br    Broad 
brs    Broad singlet 
cat.    Catalytic 
CF3SO3H(TfOH)          Trifluoromethanesulfonic acid 
CH2Cl2    Dichloromethane / Methylene chloride 
CH3CN    Acetonitrile 
δ    Chemical shift in ppm 
d    Doublet 
dd    Doublet of doublets 
dt    Doublet of triplets 
DBU    1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCC    1,3-Dicyclohexylcarbodiimide 
DCM    Dichloromethane / Methylene chloride 
DMAP    N,N-Dimethylaminopyridine 
DMSO    Dimethylsulfoxide 
ES    Electron spray 
Et3N    Triethylamine 
Et2O    Diethyl ether 
EtOAc    Ethyl acetate 
EtOH    Ethanol 
eq.    Equivalent 
FAB    Fast atom bombardment 
g    Grams 
HCl    Hydrochloric acid 
HPLC    High-pressure liquid chromatography 
hr.    Hour 
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HRMS    High-resolution mass spectrometry 
Hz    Hertz 
IR    Infrared spectrometry 
J    Coupling constant  
Lit.     Literature 
m    Meta 
m    Multiplet 
M
+
    Molecular ion 
MeOH    Methanol 
mg    Milligram(s) 
MHz    Mega hertz 
ml    Millilitre(s) 
mmol    Millimole(s) 
Mp    Melting point 
MsCl    Methanesulfonyl chloride 
m/z    Mass to charge ratio 
NBS    N-Bromosuccinamide 
NMR    Nuclear magnetic resonance 
NRTI    Nucleoside reverse transcriptase inhibitor 
o    Ortho 
p    Para 
PG    Protecting group 
P(OEt)3           Triethyl phosphite 
Pd/C    Palladium-on-carbon 
Pet ether           Petroleum ether 
PPh3    Triphenylphosphine 
(PPh3)4P           Tetrakis(triphenylphosphine)palladium (0) 
rt    Room temperature 
s    Singlet 
t    Triplet 
TBDMSCl   tert-Butyldimethylsilyl chloride 
TBDPS           tert-Butyldiphenylsilyl chloride 
td    Triplet of doublets 
TFA    Trifluoroacetic acid 
THF    Tetrahydrofuran 
TLC    Thin layer chromatography 
6 
 
TMSCl    Trimethylsilyl chloride 
p-TsOH           para-Toluenesulfonic acid  
q    Quartet 
UV    Ultra violet 
w/v    Weight by volume 
v/v    Volume by volume 
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Synthesis, Structure-Activity Relationships, Molecular Modelling and 
Cytotoxicity of 2-Aryl-1,4-Naphthoquinone-1-Oxime Methyl Ethers 
through Inhibiting Tubulin Polymerization. 
 
Chapter 1 
Introduction 
 
According to world health organisation’s (WHO), International Agency for Research on Cancer 
(IARC) figures, cancer is the leading cause of death worldwide, accounting for 8.2 million death in 
2012.
1
 Cancer is a generic term for a large group of disease that can affect any part of the body. It 
results from unique and unpredictable alteration of the genome on the cell. The cancerous genome 
may contain a number of points of mutations, translocations, fusions and other aberrations. The 
cancerous cell then rapidly create other abnormal cells which grows beyond their boundaries and 
invade adjoining parts of the body and spread to other organs, referred to as metastasis. 
 
Since the emergence of cancer, radiotherapy relatively remained a major modality of cancer therapy. 
Theoretically, radiotherapy uses high-energy X-ray or (rarely) -ray radiation to kill cancer cells by 
directly damaging DNA structure or by creating charged particles (free radicals) within the cells that 
can in turn break down the DNA. Over the decades, radiotherapy experienced great improvement 
and a sufficient dose can render any tumor cell harmless, improvements have included the use of 
megavolts ( 6-25 MV) X-rays to avoid skin damage, Intensity-modulated radiation therapy (IMRT) 
to better concentrate the dose within the shape of the tumor. But despite these advances, radio 
therapy, mostly, still fail to eradicate tumors, mainly due to emergence of hypoxic tumors, potential 
radio-toxicity to normal cells, and the end-results of cumulative damage to normal cells, which in 
turn become cancerous. 
 
In recent years, chemotherapy has emerged as a generally accepted modality in combating the 
disease. In chemotherapy, the underlying principle of the approach is to kill the cancer by treating it 
with chemicals that interfere with vulnerable processes surrounding cell division. Current 
chemotherapy regimes do this by disrupting microtubule assembly dynamics during mitosis which 
lead to cell arrest by mitotic check point complex, and eventually promoting apoptosis.
2–4
 
Microtubules are filamentous polymers that form one of the major components of the cytoskeletal 
elements of all eukaryotic cells, that are necessary for many functions, including intracellular 
transport, motility, morphogenesis and cell division.
5
  They are dynamic, ever-changing structures, 
which mean their ends are alternating between shortening and growth in a process called 
polymerization, creating a multiplicity of cell shapes in different tissue types. They can dramatically 
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and rapidly depolymerize and arrange in a single cell to form the mitotic spindle fibres that aligns 
and separates the chromosomes and can also thereby forming roadways for the transport of cellular 
cargo and are involved in intracellular signalling.
2
 They composed of alpha(α)-tubulin and 
beta(β)-tubulin heterodimers arranged in the form of slender filamentous tubes arranged head-to-tail, 
of several micrometres long.
6
  
 
Figure 1.1: Polymerization of microtubules. Heterdimers of α- and β-tubulin assemble to form a 
short microtubule nucleus, then elongation. 
 
Figure 1.2: Characteristics properties of MT dynamics 
The polymerization of microtubules occurs by a mechanism in which relatively slow formation of a 
short microtubule “nucleus” is followed by rapid elongation of the microtubule as its ends by the 
reversible, non-covalent addition of tubulin dimers. The α-tubulin subunit is always bound to GTP, 
acquiring a conformation suitable for MT polymerization, whereas the β-tubulin subunit can be 
bound either to GTP or GDP, favorable for MT polymerization or depolymerization, respectively
7
. 
Then, two ends with different dynamic properties can be distinguished within a MT: the (+)end, 
which is terminated by β subunits, being more dynamic than the (-) end, which is terminated by α 
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subunits. The dynamic instability model of MT assembly was proposed by Mitchison and Kirschner 
in 1984
8
. They proposed that individual MTs exist either in an elongation state or a rapidly 
shortening state, with abrupt and apparently random transitions between these two states. MTs are 
thus governed by an intrinsic property involving repetitive spurts of shortening from their plus ends, 
followed by periods of polymerization. This non-equilibrium behavior is based on the binding and 
hydrolysis of GTP at the nucleotide exchangeable site (E-site) in β tubulin. Only dimers that have 
GTP in their E-site can polymerize. This nucleotide is then hydrolyzed and becomes 
non-exchangeable. The GTP cap model proposes that the GDP-tubulin core of MT is stabilized at the 
plus end by a layer of GTP-tubulin subunits that may act to maintain association between 
protofilaments
9
. When this cap is stochastically lost, the protofilaments peel outward and the MT 
rapidly depolymerizes. Although both MT ends can either grow or shorten, the changes in length at 
the plus end are much greater than at the minus end. Thus, there are four variable characteristics of 
dynamic instability
7,10
: the rate of microtubule growth; the rate of shortening; the frequency of 
transition from the growth or paused state to shortening (this transition is called a ‘catastrophe’); and 
the frequency of transition from shortening to growth or pause (called a ‘rescue’). Pause is defined 
as a period when changes in microtubule length are undetectable by light microscopy and 
Dynamicity is a combination parameter, describes the overall detectable rate of exchange of tubulin 
dimers with microtubule ends. The second dynamic behavior, called ‘treadmilling’, is net growth at 
one microtubule end and balanced net shortening at the opposite end. It involves the intrinsic flow of 
tubulin subunits from the plus end of the microtubule to the minus end and is created by differences 
in the critical subunit concentrations at the opposite microtubule ends. (The critical subunit 
concentrations are the concentrations of free tubulin subunits in equilibrium with the microtubule 
ends.) This behavior occurs in cells as well as in vitro, and might be particularly important in 
mitosis
11
. Treadmilling and dynamic instability are compatible behaviors, and a specific microtubule 
population can show primarily treadmilling behavior, dynamic-instability behavior or some mixture 
of both
12
. 
 
Microtubules are exquisitely regulated by myriad of mechanisms, differentially both in different 
“regions” of a cell (e.g. during migration or mitosis). In other words, MT dynamics are regulated 
both spatially and temporally
13
. Among the mechanisms that can regulate dynamics are tubulin 
isotype expression, post-translational modification of tubulin, microtubule-associated proteins and 
microtubule-interacting proteins. With regard to tubulin isotypes, there are at least 6 α-tubulin and 
7-β tubulin human tubulin isotypes, which are expressed to varying degrees in different cells and 
tissues
14
. Post-translation modifications include polyglutamylation, polyglycylation, phosphorylation, 
acetylation, detrosination/trosination, and removal of the penultimate glutamic acid
14,15
.  MTs 
interact with an impressive number of binding proteins, and cellular MT dynamics are thus the result 
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of the combined effect of stabilizing and destabilizing factors. Regulation can occur at many levels, 
some proteins regulating tubulin folding, some stabilizing existing MTs such as structural 
microtubules associated proteins (MAPs), and some interacting with MT ends to influence their 
dynamics, location and lifespan. The main MT-related proteins that regulate MT dynamics are 
presented in Table 1
13
. 
 
 
Figure 1.3: MT interaction with the major MT-related proteins. (A) A growing MT and various 
interactions with stabilizing factors. (B) A shortening MT and various interactions with 
destabilizing factors. (–) and (+) indicate the minus and the plus ends of the MT, respectively. 
 
 
Microtubule dynamics and oncology 
Microtubule dynamics is the principal target in oncology
2,7,16
. This is mainly because microtubules 
play a critical role in cell division and during mitosis the microtubule dynamics dramatically 
increase during this phase.  At the onset on mitosis, the interphase microtubule network 
disassembles and is replaced by a new population of spindle microtubules, that is many-fold more 
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dynamic than the former
17
. It been also noted that during this phase, MAP4, which binds on the 
surface of microtubules and appears to stabilise microtubule dynamics, after being phosphorylated 
by cyclin B-cdc2 kinase, results in MAP4 less association with microtubules, which likely contribute 
to increased MT dynamics. Furthermore, nuclear envelop breakdown releases Ran, a Ras-like 
GTPase and it chromatin-bound nucleotide-exchange factor (RCC1) which also appear to regulate 
MT dynamics
18
.  Presence of RCC1 probably mediates local high concentration of Ran-GTP, which 
in turn increase MT dynamics by increased catastrophe and reduced rescue frequencies. This results 
in accumulation of very dynamics microtubules with bipolar spindle fibres in the region of the 
chromosomes
19
. 
During prophase, microtubules emanate from each of the centromeres at each pole, undergoing rapid 
catastrophe and rescue, essentially probing the cytoplasm for attachment to the kinetochore
20
. Once 
they “find” and attachment to kinetochore is achieved, it is essential that microtubules of the 
opposite pole are dynamic enough to successfully attach to sister kinetochore, resulting in a bipolar 
spindle. Once achieved, chromosomes gradually congress to the metaphase. Many 
microtubule-targeted drugs act at this stage to prevent formation of a complete bipolar spindle, as 
dynamic MTs are crucial to passage to anaphase
21
.  
 
Figure 1.4: Microtubule structures through the cell cycle. Metaphase and anaphase MTs (red), 
Telophase and interphase MTs (green), Chromosomal DNA (blue). 
 
The spindle checkpoint ensures accurate chromosome segregation in mitosis and meiosis. The 
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presence of a single chromosome that is unable to achieve a bipolar attachment to the spindle or if 
there is insufficient tension on kinetochores is sufficient to prevent a cell from transitioning to 
anaphase; the checkpoint blocks the activity of the anaphase-promoting complex. Upon checkpoint 
activation, a checkpoint protein complex containing BubR1, Bub3, Mad2 and Cdc20 binds to the 
anaphase promoting complex, inhibiting it ubiquitin ligase activity, thus the cell then remains 
blocked in a pro-metaphase/metaphase-like state and eventually undergoes apoptosis. The 
suppression of microtubules dynamics is the principal mechanism of microtubule-targeted drugs
3,4,22
.  
 
Microtubule-targeted antimitotic drugs are usually classified into two main groups. One group, 
known as the microtubule-destabilizing agents, inhibits microtubule polymerization at high 
concentrations and includes several compounds — such as the Vinca alkaloids (vinblastine, 
vincristine, vinorelbine, vindesine and vinflunine), cryptophycins, halichondrins,estramustine, 
colchicine and combretastatins. The second main group is known as the microtubule-stabilizing 
agents
23
. These agents stimulate microtubule polymerization and include paclitaxel (the first agent to 
be identified in this class), docetaxel (Taxotere), the epothilones, discodermolide, the eleutherobins,  
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sarcodictyins, laulimalide, rhazinalam, and certain steroids and polyisoprenyl benzophenones
24,25
. 
This classification is based on that microtubule-targeted drugs increase or decrease microtubule 
polymerization at high concentrations powerfully suppress microtubule dynamics at 10–100-fold, 
therefore, kinetically stabilize the microtubules, without changing the microtubule-polymer mass. 
This discovery is contract to the previously held thought that the effects of the two classes of drugs 
on microtubule polymer mass were the most important actions responsible for their 
chemotherapeutic properties. The current held dogma is that these drugs suppression of 
spindle-microtubule dynamics, which results in the slowing or blocking of mitosis at the metaphase–
anaphase transition and induction of apoptotic cell death
26,27
. 
 
Mechanisms of microtubule-targeted drugs 
The Vinca alkaloids (vinblastine and vinscristine) were isolated from the leaves of the periwinkle 
plant Catharanthus roseus (L.) G. Don.
28
 The leaves of the periwinkle plant have been used for their 
medicinal properties since the seventeenth century. These drugs have been found to depolymerize 
microtubules and destroy mitotic spindles at high concentrations in Hela cells, thus blocking mitosis 
14 
 
in the dividing cell with condensed chromosomes. While at low, but within clinical concentrations, 
they were found to suppress microtubule dynamics rather than microtubule polymerization
27
.  
The clinically approved vinblastine binds to tubulin and also directly to microtubules, in the 
β-subunit of tubulin dimers at a distinct region referred as Vinca binding domain. Vinblastine binds 
rapidly and reversibly to tubulin and induces conformational change in tubulin which increases it 
binding affinity to tubulin. This ability is thought to play a key role in the ability of the drug to 
stabilize microtubules kinetically
29
. 
 
 
Figure 1.5. Antimitotic drugs bind to microtubules at diverse sites. a A few molecules of vinblastine 
bound to high-affinity sites at the microtubule plus end suffice to suppress microtubule dynamics. B 
Colchicine forms complexes with tubulin dimers and copolymerizes into the microtubule lattice, 
suppressing microtubule dynamics. c A microtubule cut away to show the interior surface is shown. 
Paclitaxel binds along the interior surface of the microtubule, suppressing its dynamics. 
 
Paclitaxel and related drugs 
On the other, taxol binds poorly to soluble/ non-polymerized tubulin dimers, but with high affinity to 
tubulin along the interior length of the microtubule. Binding of paclitaxel to its site on the inside 
microtubule surface stabilizes the microtubule and increases microtubule polymerization, 
presumably by inducing a conformational change in the tubulin that
5
, by an unknown mechanism, 
increases its affinity for neighboring tubulin molecules 24. There is one paclitaxel-binding site on 
every molecule of tubulin in a microtubule and the ability of paclitaxel to increase microtubule 
polymerization is associated with nearly 1:1 stoichiometric binding of paclitaxel to tubulin in 
15 
 
microtubules
30
. 
 
Colchicine 
Colchicine is used clinically in the treatment of gout, but including colchicine-related compounds 
they are not used for the treatment of cancer. This has been said to be attributed by their potent 
toxicity. Currently several other compounds that bind to the colchicine binding site are under 
investigation. The interaction of colchicine with tubulin and microtubules presents yet another 
variation in the mechanisms by which microtubule-active drugs inhibit microtubule function. While 
it in many ways similar to that of Vinca alkaloids, in that colchicine depolymerizes microtubules at 
high concentrations and stabilizes microtubule dynamics at low concentrations; Colchicine inhibits 
microtubule polymerization sub-stoichiometrically as oppose to Vinca alkoloids (i.e. at 
concentrations well below the concentration of the tubulin that is free in solution). It is thought that 
colchicine inhibits microtubule polymerization by binding to microtubule ends rather than to the 
soluble-tubulin pool. Colchicine probably does not bind to microtubule ends as with Vinca alkaloids, 
rather on soluble tubulin, thereby inducing conformational changes leading to a poorly reversible 
final state tubulin-colchicine complex. This complex then copolymerizes into the microtubule ends 
in small numbers along large numbers of free tubulin molecules. While new tubulin addition is not 
affect, but microtubule dynamics became suppressed. The principle for suppression being that, the 
incorporated complex should bind more tightly to its neighbors then tubulin itself; hence the rate of 
catastrophe is reduced (for review, see ref 2 and others within).  
Despite differences in the mode of action between Vinca colchicine-like drugs and the taxane-like 
drugs, nearly all of the microtubule-targeted drugs stabilizing microtubule dynamics at their lowest 
effective concentrations, the suppression/stabilization of microtubule dynamics correlate with 
blocking of the cell cycle at mitosis and in sensitive tumor cells, ultimately resulting in cell death by 
apoptosis. Therefore, the most potent mechanism of nearly all of the microtubule-targeted drugs 
seems to be stabilization of dynamics of mitotic-spindle microtubules
31
.  
 
Quaternary benzo(c)phenanthridines 
 
Quaternary benzo(c)phenanthridines alkaloids are produced by a number of plant species of the 
Papaveraceae, Fumariaceae, and Rutaceae families
32
. Herbal extracts from the aforementioned plants 
have been utilized in folks medicine as antimicrobial, antifungal, and anti-inflamatory agents
33
 . 
They are fully-aromatized alkaloids with an isoquinoline core skeleton and are structurally classified 
in O4-type (R
1
, R
2
, R
3
, R
4
 or R
1
, R
2
, R
4
, R
5
 = OR), O5-type (R
1
, R
2
, R
3
, R
4
, R
6
, R
7
 = OR) and O6-type 
(R
1
, R
2
, R
3
, R
4
, R
6
, R
7
 = OR) bases dependent upon the number of oxygen functions in their 
molecules, Figure 1.6
34
. These naturally occurring plant-based alkaloids has displayed an attractive 
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biological activity as antiprolification agents
32,35
. Among the O4-type, the list include nitidine
36
, 
NK109
37
, and sanguinarine(SA)
37
  chelerythrine (CHE)
32
 being the best recognized ones.  
Macarpine, an antitumor-active O6-benzo[c]phenanthridine alkaloid has been greatly discussed as 
potential cytostatic for cancer treatment. Macarpine is only one naturally occurring O6-base alkaloid 
firstly isolated by Slavik et al
38
. In an ongoing research, in Chiba University laboratory by Ishikawa 
et al.
39
 they have reported the synthesis of a macarpine using a synthetic strategy base on nitrosation 
of 1-naphthol followed by the Bischler-Napieralski reaction (BNK) of naphthylformamide. In this 
study, cytotoxic activity of marcarpine (in it chloride form) was tested on HeLa S3 tumor cell and 
compared to those of the structurally related 2, 3.7, 8, 10-pentaoxygenated (O5) base chlorides, 
10-isopropoxysanguinarinel and chelilutine chlorides. Interestingly, marcapine showed the strongest 
activity among them. On the other hand the least one was observed in chelilutine. In other words 
additional introduction of a methoxy group into the C2 position of a benzo[c]phenanthridine 
skeleton may cause to enhance the activity, while replacement of a methylenedioxy function at the 
7,8 positions by two methoxy groups led to reduction of the activity. These compounds and it 
intermediates are the subject of this thesis. 
 
Figure 1.6: Structures of Benzo[c]phenanthridine Alkaloids 1a-e, Naphthoquinone Monooxime ether 
2, and 2-aryl-naphthoquinone-1-oxime methyl ether 3. 
 
In screening for the discovery of potential anti-tumor active seed compounds, the intermediate QO-1 
showed string cytotoxic activity against a number of cell lines. It was also found that QO-1 induced 
G2/M-phase arrest in Hela and MCF-7 cells
40
, possibly by inducing microtubule-depolymerization 
effects similar to that of nocodazole. This was supported by expression of Bub1, one of the spindle 
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assembly checkpoint (SAC) proteins. 
Preliminary experiments on the structure activity-relationship (SAR) of the 
6,7-methylenedioxy-1,4-naphthoquinone-1-oxime methyl ether skeleton
34
, a common core structure 
in the 2-aryl-1,4-naphthoquinone-1-oxime methyl ether derivatives, suggested that it play an 
important role for the activity of these compounds (see Figure 1.6, structure 3). In these 
aforementioned studies, 2 (or QO-1) cytotoxicity was evaluated using Hela S3 cell by methylene 
blue staining method and the IC50 was estimated to be less than 0.1 ug/ml using Litchfield and 
Wilcoxon method. Using these results as a positive control for SAR examination, it was found that 
displacement of the methylenedioxy moieties either in the naphthoquinone skeleton or in the 2-aryl 
substituent with dimethoxy ones led to reduction of activities. Replacement of both methylene 
moieties resulted in loss of activity. Furthermore, structural modification of the skeletal core unit of 
1,4-naphthoquinone-1-oxime ethers, either the 1,4-naphthoquinone substituents or modification of 
the oxime moiety, resulted in total loss of activity, hence revealing crucial requirement of the 
functional 6,7-methylenedioxy-1,4-naphthoquinone-1-oxime methyl ether skeleton in spite of 
substituent tolerance in the 2-aryl group. 
 
Objectives of this thesis 
 
To further explore the SAR and optimize the lead compound 2, we planned to 1) synthesis 
2-aryl-1,4-naphthoquinone-1-oxime methyl ether analogues by modification of the 2-aryl group; 2) 
biological activity and molecular docking studies of aryl-modified 1,4-naphthoquinone-1-oxime 
methyl ether.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18 
 
Chapter 2 
Results and Discussion 
 
Synthetic Plan 
The 2-aryl-1,4-naphthoquione-1-oxime methyl ether compounds were synthesized as outlined in 
Scheme 2.1. First, the phenyl ring was modified into appropriate tert-butyl o-bromobenzoate 4, 
consisting of appropriate ether.  In a modified literature procedure
41
 we employed Osium oxidation, 
dihydroarnottin II 6 was prepared from oxidation of dihydroarnottin I 5 with Osium tetroxide in a 
presence of N-methylmorpholine N-oxide (OsO4-NMO) as a sacrificial catalyst. Dihydroarnottin I 5 
was directly prepared by palladium-catalysed coupling of o-bromobenzoate (4) and 
6,7-methylenedioxy-1-tetralone (3) using Buchwald protocol
42
.  Dihydroarnottin II 6 was 
subsequently hydroxylated with NBS and water to give 7, then transformed into a methyl ether 
oxime 8 in the presence of methyl hydroxylamine-hydrochloric acid in pyridine. We found that, in 
some cases, bromination resulted in 3,4-dibromination (see experimental, 7), in this case, we were 
able to selectively hydrolyse C-4 position to give a C-3-bromo-C4-hydrox-1- ketone, and the 
debromination was achieved by palladium catalysed reaction. Finally, 
2-aryl-1,4-naphthoquinone-1-oxime methyl ethers 9 were obtained by IBX oxidation in DMSO at 
elevated temperatures.  The 2-aryl-1,4-naphthoquinone-1-oxime were then treated with methyl 
iodide employing potassium carbonate as a base in DMF to achieve desired ester 10a.  
 
Scheme 2.1: Synthetic route of 2-aryl-1,4-naphthoquinone-1-oxime methyl ether. 
 
The synthesis of the required ester 14 is depicted in Figure 2.1. It was envisaged that the 
commercially available phenol 11 would be the best starting point.  The required ester 14 could be 
obtained from a suitably functionalised acid intermediate which can be obtained from ester 13, via 
hydrolysis followed by esterification. The halogenated phenyl methyl ester 13 could be obtained 
from halogenation of the benzyl protected ether 12, which in turn was obtainable from the 
commercially available phenol 11. 
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Figure 2.1: Synthetic procedure for ester 14. 
 
Thus the phenol 1 was subjected to etherification using the modified condition of Pouysegu et.al
43
 
employing benzyl bromide in DMF at elevated temperature of 100 
o
C, in the presence of potassium 
carbonate as an acid scavenger to give 100% the benzyl ether 2 after column chromatography 
(Scheme 2.2) which was confirmed by NMR 5.17 ppm, 13C NMR at 71.04 ppm benzyl methelene 
peak. The Hathway et al
44
 silver nitrate mediated halogenation conditions, failed to achieve neither 
iodate nor brominate the substrate, resulting in quantitative recovery of starting material and Further 
modifications (entry 2) also was inadequate to archive halogenated compound. Noteworthy, in the 
proceduere by Carme Pampin et al
45
, when hypervalent iodide was employed (entry 3, and other 
case such as TMDACl
46
, not shown), resulted in the removal of the benzyl protecting group, 
resulting back to phenol 1. Attempts to modify the procedure, by either varying the concentration of 
triflic acid or adjusting temperature proved inadequate.  
 
Scheme 2.2: Trials for the synthesis of ester 13a or 14b. 
 
The above results prompted modification to the experimental procedure; it was assumed that the 
presence of electron withdrawing groups rendered the aryl group unreactive. Taking this to 
consideration, the commercially available aldehyde 15 (vanillin) was chosen as a starting point, 
opting to introduce the ester at later stage (Scheme 2.3). 
20 
 
 
 
Scheme 2.3: Reagents and Conditions.a) K2CO3, BnBr, DMF, 100 
o
C, 2h.; b) AgNO3, Br2, MeOH, rt, 
16h.; c) NaH2PO4, NaClO2, H2O2, H2O, MeCN, rt, 2h.; d) CCl3C(NH)O
t
Bu, BF3.Et2O, 
DCM-cyclohexane. 
 
The revised approach, the synthesis of the benzyl ether 16 was performed similarly as above. 
Examining the halogenation of 16 employing the Hathway et. al procedure, were able to achieve the 
brominated compound 17 in good yield. Other general methods such as AcOH/Br2 were not 
successful, or giving low yield ca. 20% yield. Oxidation of the aldehyde 17 was achieved via Pinikin 
Oxidation procedure in excellent yield. In this procedure, upon disappearance of the starting 
aldehyde, the reaction was acidified with diluted (10%) HCl, then the crude acid obtained by 
extraction with EtOAc give crude acid 18 as a colorless solid , which was used in next step without 
further purification. Subjecting the crude acid to esterification conditions employing t-BuOH in the 
presence of catalystic amounts of MgSO4 resulted in recovery of the starting material without 
detection of the product. On the other hand, esterification using imidate in the presence of catalytic 
Bf3.Et2O gave the desired t-butyl ester 14b, in satisfactory yield. We decided to optimize these 
conditions, and we found that increasing or decrease the lewis acid lowered the yield, but increasing 
the time length has a positive effect on the yield, 20 h being the optimum time. 
 
We then turned our attention to the preparation of 3. There are two procedures that were identified in 
literature. The first procedure is illustrated of scheme 2.4 below. 
 
 
Scheme 2.4: Reagents and Conditions. a)NaH, DMSO-THF (1:1), rt, 24 h.; b)H2, Pd/C, THF, rt, 3h.; 
c) POCl3, K2CO3, MeCN, 2h, rt 
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Compound 20
47
 was prepared by refluxing the commercially available propionic acid and triphenyl 
phosphine in CH3CN for 24 h in accordance with the published procedure, which was then subjected 
to the Witting reaction of aldehyde 19 and the acid 20, to give the desired enoic acid 21. The enoic 
acid was reduced by palladium-mediated hydrogenation and upon filtration in Celite, without further 
purification the resulting crude product was subjected Freidel-Craft acylation with POCl3
48
. All 
spectroscopic data were identical with reported. Unfortunately this procedure presented great 
difficulties in scaling up; hence we further examined an alternative method, as shown in Scheme 2.5. 
 
Scheme 2.5: Reagents and Conditions. a) AlCl3, DCM, 40 
o
C, overnight.; b) 1) Pd/C (cat), H2, AcOH, 
rt, 24 h., 2) POCl3, K2CO3, MeCN, rt, 2h.; c) HBr, AcOH, 110 
o
C, 2h.; d) BrCH2Cl, Cs2CO3, 110 
o
C, 
1.5 h. 
 
The 1-tetralone 25 was synthesized employing the Haworth synthesis. Briefly, 1,2 methoxybenzene 
22 was reacted with succinic anhydride 23 by a Friedel–Crafts acylation, the intermediate γ-keto 
acid 24 product was then reduced by palladium mediated hydrogenolyis, then a second Friedel–
Crafts acylation mediated by POCl3 gave product 25, which was then subjected to de-methylation 
employing 30%HBr in Acetic acid at elevated temperatures to give the di-hydroxyl 26. The product 
26 was alkylated with bromochloromethane in DMF, to give the desired product 3. We found this 
approach scalable to multi-gram scale and all spectroscopic data was compared to the published 
data. 
 
We then synthesized dihydroarnottin I 27, in a Palladium (Pd)-catalysed reaction in the presence of 
2-bromobenzoate 14b and 1-tetralone 3. This was a key step to the reaction.  Dihydroarnottin II 28 
was achieved via OsO4 oxidation in the presence of NMO as a cooxidant catalyst.  
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Scheme 2.6 : Reagents and Conditions.a) Pd(dba)3, Cs2CO3, Xantphos, Na2S2O5, toluene, 100 °C, 48 
h, argon, 81%.; b) OsO4, NMO, CH2Cl2–acetone, r.t., 5 d, 86%.; c) (1) NBS, AIBN, benzene, 70 °C, 
3 h; (2) acetone, H2O, 40 °C, 20 h, 30a, 25%, 30b, 40%.  
 
We encountered problems with hydroxylation of 28 as the desired product 29 was not observed 
rather other two products were observed, 30a and 30b. Detailed analyses showed that, 
de-benzylation occurred before hydroxylation. Selective protection studies indicated that, as 
expected, the secondary hydroxyl was more reactive that the phenol group. This implied that a 
laboratory intensive selective protecting and selective de-protection. While there was a possibility of 
changing the benzyl protecting group, we rather opted for oximation to be succeeded by 
hydroxylation.  
Preliminary oximation (Figure 2.7) of the spiro tetralone 28 resulted in the benzylated 31 and 
non-benzylated 32 oximes, implying the instability of the benzyl ether both under radical and acidic 
conditions. We then decided to remove the benzyl ether under Palladium (Pd)-catalysed hydrolysis, 
resulting in many un-resolvable spots/poor yield. We found that, the same hypervaled iodide 
reagents (see Scheme 2.2), used earlier in attempting to iodinate 12, works best. We then engaged 
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into optimizing this reaction exploring Aromatic benzyled-ethers (Ar-OBn) (results not shown). We 
found that the reactions satisfactory gave the end-product. During optimization, we found that the 
hypervaled iodide could be used catalytically in these conditions to give a pure product and 
furthermore, the reaction rate was directly proportion to amount of an acid used. Upon this discovery, 
we decided to perform a two-step reaction, de-benzylation followed by oximation to achieve methyl 
oxime ether 32. Upon acetylation of 32, we then attempted hydroxyl group insertion, on the spiro 
oxime 33, applying the aforementioned AIBN/NBS conditions. In an unexpected outcome, 
additional bromine-incorporated oxime 34 resulted (Scheme 2.8). 
 
 
Scheme 2.7: Reagents and Conditions. a) NH2OMe·HCl, pyridine, 90 °C, 12 h, 31, 20%, 33 35%. b) 
(1) TfOH, IPy2BF4, CH2Cl2, 0 °C, 20 min; (2) NH2OMe·HCl, pyridine, 90 °C, 12 h 98%. c) Ac2O, 
Et3N, I2, THF, 40 °C, 7 h, 90%. 
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Scheme 2.8 : Reagents and Conditions. a) 1) NBS, AIBN, benzene, 70 °C, 3 h; 2) acetone, H2O, 
40 °C, 20 h, 29%; b) 1) IBX, DMSO, 50 °C, 2 h; 2) Et3N, CH2Cl2, r.t., 2 h, 99%; c) MeI, K2CO3, 
DMF, r.t., 2 h, 65%; d) Pd(OAc)2, K2CO3, PPh3, BuOH, 100 °C, 2 h, 93%. 
The 3-bromo-oxime 34 was then employed in the direct construction of the 1,4-naphthoquinone 
1-oxime 35  by oxidation with hypervalent-iodine (IBX) in DMF at elevated temperatures. 
Conventional esterification of 35 with MeI and potassium carbonate in DMF gave ester 36. 
Palladium mediated reductive debromination of 36 smoothly afforded the target 1,4-naphthoquinone 
1-oxime 10a.  
 
Synthesis of conjugated-AK25 
In the previous investigation for cyctotoxicity of 10b, it was determined that low solubility in DMSO 
resulted in limited potency. We then undertook to introduce an amino acid-based conjugated. We 
considered introducing glycine-; n =2 , β-alanine- and n = 3, γ-aminobutyric acid-based conjugated 
10b, as shown in Figure 2.2.  
 
Figure 2.2: The synthetic conjugate. 
 
Compound 10b was synthesized as previously reported. We started by investigating the possibility of 
forming the conjugated salicylate 38 and employing N-protected glycine residue as show in Figure 
2.3. 
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Figure 2.3: Model reaction for synthesis of conjugate 39 (below). 
We found condensation with DCC in the presence of catalytic DMAP in-efficient, resulting in 
recovery of strting material. Similarly, acid chlorides from thionyl chloride and oxalyl choride also 
resulted in no formation of the products after 24 h. BOP 
[(Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate] finally achieved the 
product but rather in unsatisfactory yield of 25%. To ease TLC analysis, we decided to employ the 
UV active N-Cbz-glycine. HATU further improved the yield, giving the product in 83% yield in 16 h 
at room temperature. We then decide to use these conditions for preparation of our conjugates. 
 
Scheme 2.9: Synthesis of conjugates 39 a-c employing HATU. 
 
Employing excess amount of the amino acid (2 eq), we were able to achieved satisfactory yields in 
all conjugates, glycine (84%), β-alanine (78%) and γ-butyric acid (89%). The conjugates showed an 
improved polarity, compared to it precursor 10b. The conjugates could be de-protected but due to 
time constrains, we choose not to remove the Cbz-group. It would be worth to mention that we have 
hoped to form a water-soluble amine-hydrochloric acid (RNH2·HCl) type conjugate. The biological 
results would be discussed in the next section. 
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Chapter 3 
Biologic Results 
 
The synthesized compounds, 10a, 39a, 39b and 39c were evaluated in vitro as inhibitors of tubulin 
(de)-polymerization for Hela (cervix). The results are shown in table below.  
 
 
Figure 3.1: Synthesized compounds and their biological activity. 
 
The antiproliferative activities of the newly synthesized compounds were then tested against Hela 
cell lines. The in vitro activities, expressed as IC50 values in micrograms per milliliter together with 
that of 31b, the most active compound in previous in vitro tests and 2, the lead compound. 
Compounds shown with IC50 values greater than 10 (>10), showed low antiproliferative activities 
due to their poor solubility in aqueous solution which prevented a reliable evaluation of their in vitro 
activities. It is also worth mentioning that, in order to obtain comparable biological tests, 
experiments were performed and were all measured with same instruments. The percent of growth 
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and the inhibition exerted by different doses (0–10 μM or LogM) are recorded. 
Molecular modeling studies were performed with compounds 10a, 10b and 2 in order to investigate 
their possible interactions with the amino acid residues in the active site of colchicine binding site. 
 
 
Figure 3.2: A) Binding of Colchine (yellow) and 10a (green), B) Binding of Colchicine 
(yellow) and 10b (green). 
Crystallographic structure of binding pocket residues of tubulin was obtained from 
protein database (pdb code: ISA0). The binding pocket of the colchicine has been very 
well described at the present. We than focused on the binding modes of the most active 
compound 31 to tubulin, compound 31 assumed a conformation in the same binding 
region of colchicine. The 2-aryl group of 31 was positioned in a similar orientation of 
the corresponding ring trimethoxy of the colchicine. The docking score of 31 (64.12) 
showed more potency than colchicine (57.59), hence we decided specific research on 
the binding of these aforementioned ligands (Figure 3B). Notably, both colchicine and 
31 have hydrophobic interaction with leu255 and furthermore, both form a hydrogen 
interaction with lys254. The higher potency of 31 might be primarily due to differences 
in pKa of the phenol of 31 as oppose to the amide bond of the colchicine. The lower 
pKa of phenol increases the hydrogen bonding strength as it been observed in other 
cases
49
. Interestingly enough, 28 showed the highest affinity, with a mode almost 
similar to 31, but the compound was biologically inactive. 
 
 
B A 
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Chapter 4 
Experimental Section 
Molecular Docking 
X-ray crystal structure of α/βtubulin (PDB code 1SA0) was retrieved for docking studies. The structure 
was used as obtained. In order to evaluate the interaction between the naphthoquinone derivatives and 
tubulin protein, we have executed the docking simulation using GOLD 3.2 (CCDC Software Ltd., 
Cambridge, UK). The three-dimensional structures of the naphthoquinone derivatives used in this 
study were optimized by semiempirical PM3 method. GoldScore was chosen as a fitness function 
and the standard default settings were used in all calculations. On the basis of score, top scored 
docking structures were visually inspected for each ligand. The molecular interactions were 
visualized by Pymol 1.3. 
 
Cytotoxicity Assay 
In vitro anticancer activity of compounds using MTT assay. Cytotoxicity testing in vitro was done by 
the method of Woerdenbag et al.
1
  2 × 10
3
 cells/well were incubated in the 5% CO2 incubator for 
24 h to enable them to adhere properly to the 96-well polystyrene microplate (Grenier, Japan). Test 
compound dissolved in 100% DMSO (Merck, Japan) in at least five doses was added and left for 6 h 
after which the compound plus media was replaced with fresh media and the cells were incubated for 
another 48 h in the CO2 incubator at 37 °C. The concentration of DMSO used in our experiments 
never exceeded 0.1%, which was found to be non-toxic to cells. Then, 10 μl MTT 
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma] was added, and plates were 
incubated at 37 °C for 1 h. One hundred microlitres of dimethyl sulfoxide (DMSO, Merck, Japan) 
was added to all wells and mixed thoroughly. After a few minutes at room temperature to ensure that 
all crystals were dissolved, the plates were read on a SpectraMax 190 Microplate Elisa reader 
(Multiskan JX, labsystems) at 540 nm. Plates were normally read within 1 h of adding the DMSO. 
The experiment was done in triplicate and the inhibitory concentration (IC) values were calculated as 
follows: 
 
             
[    (      )         ]
[   (      )              ]
x100 
 
IC50 is the concentration μM required for 50% inhibition of cell growth as compared to that of 
untreated control 
                                                   
1 Woerdenbag, H. J.; Moskal, T. A.; Pras, N.; Malingre, T. M.; el-Feraly, F. S.; Kampinga, H. H.; 
Konings, A. W. Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells. J. 
Nat. Prod. 1993, 56, 849-856. 
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Chemistry 
General procedure 
Unless noted otherwise, Reactions were carried out under argon atmosphere, all reagents and 
solvents we used as purchased without further purification. Analytical TLC was performed using 
silica gel 60 F254 plates (Merck) or RP-18 F254s plates (Merck). Flash column chromatography was 
performed on silica gel 60 (70-230 mesh, Merck). 
1
H-NMR (400 MHz) and 
13
C-NMR (100 MHz) 
spectra were recorded on JEOL JNM ECP 400 in CDCl3 unless otherwise stated. Coupling constants 
(J) are reported in hertz, and chemical shifts are reported in parts per million (δ) relative to CDCl3 
(7.26 ppm for 
1
H and 77.00 ppm for 
13
C). Melting points are uncorrected. IR spectra were recorded 
on a JASCO IR-300E spectrometer (ATR). High Resolution (HR)-FAB-MS and HR-electrospray 
ionization (ESI)-MS spectra were measured by JEOL JMS-HX 110A and JMS-T100LP and Thermo 
Scientific Exactive Bentitop Orbitrap spectrometers, respectively.  
 
4-Benzyloxy-2-bromo-5-methoxybenzoic Acid (18) 
To a solution of 4-benzyloxy-2-bromo-5-methoxybenzaldehyde (1.18 g, 3.69 mmol) in MeCN (15 
mL) was added a solution of NaH2PO4 (0.133 g, 1.11 mmol) in H2O (3.7 mL) and H2O2 (0.46 mL, 
4.43 mmol), and then a solution of NaClO2 (0.468 g, 5.17 mmol) in H2O (7.4 mL) was dropwise 
added under ice-cooling. After stirred at r.t. for 2h, the mixture was acidified with diluted HCl (pH 
ca. 3) and extracted with EtOAc (10 mL×2). The combined organic solutions were washed with H2O 
(10 mL×3) and brine (15 mL), dried (Na2SO4), and evaporated to give acid (1.17 g, 94%) as white 
solid. Mp: 182-183 °C (CH2Cl2); IR: 2923, 1683 cm
-1
; 
1
H NMR: δ = 3.89 (s, 3H), 5.17 (s, 2H), 6.70 
(br. s, 1H), 7.18 (s, 1H),7.34-7.45 (m, 5H),7.58 (s, 1H); 
13
C NMR: δ = 56.2, 71.0, 115.0, 118.9, 121.7, 
127.7, 128.5, 128.6, 135.5, 139.6, 148.), 151.9, 169.5; HR(ESI)MS: m/z calcd for C15H14BrO4: 
337.00755; found: 337.00909 . 
 
tert-Butyl 4-Benzyloxy-2-bromo-5-methoxybenzoate (14b) 
To a stirred mixture of acid (0.300 g, 0.89 mmol) in CH2Cl2 (1mL) was added a solution 
of tert -butyl 2,2,2-trichloroacetimidate (0.32 mL, 1.78 mmol) in cyclohexane (3 mL) at r.t. and a 
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small amount of BF3.OEt2 (2 drops) after 5 min. The mixture was stirred at r.t. for 16 h, quenched 
with H2O (10 mL), extracted with EtOAc (15 mL). The combined organic solutions were washed 
with brine (5 mL×2), dried, and evaporated. Column chromatography of the residue (hexane : 
EtOAc = 5 : 1) afforded ester (0.437 g, 75%) as white powder, mp 115-116 °C. IR: 1702 cm
-1
; 
1
H 
NMR: δ = 1.61 (s, 9H), 3.89 (s, 3H), 5.14 (s, 2H), 7.10 (s, 1H), 7.31-7.43, (m, 6H); 
13
C NMR: δ = 
28.6, 56.2, 71.2, 82.4, 113.1, 114.5, 118.8, 125.8, 127.6, 128.4, 128.8, 135.9, 148.5, 150.8, 165.3; 
HR(ESI)MS: m/z calcd for C19H22BrO4: 393.07015; found: 393.07015. 
 
9-Benzyloxy-8-methoxy-2,3-methylenedioxy-6H-benzo[d]-3,4-dihydronaphtho[1,2-b]pyran-6-o
ne (27) 
According to the reported procedure,
6
 a mixture of bromobenzoate 14b (65 mg, 0.166 mmol), 
tetralone 6 (38 mg, 0.200 mmol), Pd2(dba)3 (16 mg, 0.017 mmol), xantphos (19 mg, 0.033 mmol), 
Cs2CO3 (163 mg, 0.500 mmol), and Na2S2O5 (3 mg, 0.017 mmol) in toluene (1 mL) was stirred at 
100 °C for 36 h. Workup followed by washing the black-gray precipitate  with Et2O (5 mL x 4) 
afforded 27 as gray solid (69 mg, 81%). Mp 213-216 
o
C (EtOH); IR: 1748 cm
-1
; 
1
H NMR: δ = 2.75 
(t, J = 8.4 Hz, 2H), 2.88 (t, J = 7.8 Hz, 2H), 5.29 (s, 2H), 5.96 (s, 2H), 6.68 (s, 1H), 6.94 (s, 1H), 
7.32 (s, 1H), 7.33-7.50 (m, 5H), 7.69 (s, 1H); 
13
C NMR: δ = 21.5, 27.6, 56.4, 71.2, 101.4, 103.5, 
105.0, 107.8, 108.5, 110.6, 113.9, 122.9, 127.4, 128.5, 128.9, 130.9, 133.1, 136.0, 146.8, 147.5, 
148.0, 149.5, 162.0; HR(ESI)MS: m/z calcd for C26H20O6: 429.13381; found: 429.13476. 
 
6,7-Methylenedioxy-1-tetralone-2-spiro-3'-(6-benzyloxy-7-methoxyphthalide) (28) 
According to the reported procedure,
6
 a mixture composed of the lactone 27 (0.700 g, 1.63 mmol), a 
solution of OsO4 (0.041 g, 0.163 mmol), and NMO (0.951 g, 8.12 mmol) in acetone (7.5 mL) and 
CH2Cl2 (7.5 mL) was stirred at r.t. for 5 days. After addition of Na2SO3 (1.20 g, 8.12 mmol) workup 
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followed by column chromatography (hexane :  EtOAc = 1 : 1) afforded spiro tetralone 28 as 
colorless solid (0.624  g, 86%). Mp 239-240 °C (EtOAc); IR: 1678 cm
-1
; 
1
HNMR: δ = 2.35 (ddd, J 
= 13.7, 5.8, 5.8 Hz, 1H), 2.60 (ddd, J = 13.7, 8.6, 5.2 Hz, 1H), 2.99 (ddd, J = 17.8, 8.6, 5.2 Hz, 1H), 
3.21 (ddd, J = 17.6, 5.8, 5.8 Hz, 1H), 3.94 (s, 3H), 5.08 (d, J = 10 Hz, 1H), 5.16 (d, J = 11 Hz, 1H), 
6.08 (s, 1H), 5.16 (s, 1H), 6.63 (s, 1H), 6.72 (s, 1H), 7.27-7.34 (m, 6H), 7.41 (s, 1H); 
13
C NMR: δ = 
26.2, 33.9, 56.5, 71.4, 85.8, 102.4, 106.3, 107.2, 107.6, 108.2, 118.6, 125.9, 127.3, 128.4, 128.8, 
135.8, 140.3, 142.4, 147.8, 151.7, 153.3, 153.7, 169.9, 188.7; HR(ESI)MS: m/z calcd for 
C26H20NaO7: 467.11067; found: 467.10307. 
 
1-Methoxyimino-6,7-methylenedioxy-1,2,3,4-tetrahydronaphthalene-2-spiro-3-(6-hydroxyl-7-m
ethoxyphthalide) (32) 
A mixture of triflic acid (0.21 mL, 2.37 mmol) in DCM (1 mL), was dropwise added to an ice-cooled 
solution of 28 (0.351 g, 0.790 mmol) and IPy4BF4 (0.059 g, 0.158 mmol) in CH2Cl2 (30 mL). The 
mixture was stirred at 0 °C for 20 min, quenched with ice-H2O (20 mL), and extracted with CH2Cl2 
(15 mL). The combined organic solutions were washed with brine (20 mL×2), dried, and evaporated. 
The brownish oily residue was dissolved in pyridine (30 mL) and NH2OMe.HCl (0.659 g, 7.896 
mmol) was added. The mixture was stirred at 90 
o
C for overnight, quenched with saturated solution 
of CuSO4 in H2O (50 mL), and extracted with EtOAc (20 mL×3). The combined organic solutions 
were washed with H2O (20 mL) and brine (20 mL), dried, and evaporated. Column chromatography 
of the residue (hexane : EtOAc = 5 : 2) afforded 32 (0.298 g, 98%) as gum. IR: 3420, 1747 cm
-1
;
 1
H 
NMR: δ = 2.09 (m, 2H), 2.80 (ddd, J = 16.0, 5.8, 3.8 Hz, 1H), 3.03 (ddd, J = 15.2, 10.4, 4.2 Hz, 1H), 
3.61 (s, 3H), 3.99 (s, 3H), 5.96 (s, 1H), 5.98 (s, 1H), 6.66 (s, 1H), 6.80 (s, 1H), 7.31 (s, 1H), 7.40 (s, 
1H), 8.60 (br. s, 1H); 
13
C NMR: δ = 26.2, 37.9, 56.3, 62.7, 82.5, 101.1, 105.2, 106.3, 107.6, 117.8, 
124.0, 133.5, 145.3, 147.1, 147.6, 147.9, 149.1, 151.8, 170.6, 171.1; HR(ESI)MS: m/z calcd for 
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C20H18NO7: 384.10833; found: 384.10868 . 
 
1-Methoxyimino-6,7-methylenedioxy-1,2,3,4-tetrahydronaphthalene-2-spiro-3-(6-acetyloxy-7-
methoxyphthalide) (33) 
A solution of 32 (0.142 g, 0.367 mmol), Et3N (0.51 mL, 3.67 mmol), Ac2O (0.35 mL, 3.67 mmol), 
and catalytic amount of iodine (~5mg) in THF (3 mL) was stirred at 40 
o
C for 7 h, diluted with 
saturated solution of Na2S2O3 in H2O (10 mL), and extracted with EtOAc (5 mL×3). The combined 
organic solutions were washed with brine (10 mL), dried, and evaporated. Column chromatography 
of the residue (EtOAc : hexane = 2 : 3) afforded 33 (0.141g, 90%) as a light-brown oil. IR: 1764 
cm
-1
; 
1
H NMR: δ = 2.30 (s, 3H), 3.60 (s, 3H), 3.91 (s, 3H), 5.95 (s, 1H), 5.97 (s, 1H), 6.65 (s, 1H), 
6.99 (s, 1H), 7.39 (s, 1H), 7.43 (s, 1H); 
13
C NMR: δ = 20.4, 26.3, 37.9, 56.4, 62.9, 82.7, 101.4, 105.0, 
107.8, 108.0, 115.6, 123.8, 124. 8, 133.4, 144.8, 145.4, 147.2, 149.2, 152.4, 168.3, 169.9, 171.1; 
HR(ESI)MS m/z: Calcd for C22H20NO8: 426.11889; found: 426.11978 
 
1-Methoxyimino-3-bromo-4-hydroxy-6,7-methylenedioxy-1,2,3,4-tetrahydronaphthalene-2-spir
o-3-(6-acetyloxy-7-methoxyphthalide) (34) 
A mixture of 33 (222 mg, 0.521mmol), NBS (185. mg, 1.042 mmol), AIBN (9 mg, 0.052 mmol) in 
benzene (10 mL) was stirred at 70 
o
C for 3h and diluted with EtOAc (15mL). The mixture was 
washed with H2O (10 ml x 2) and brine (10 mL), dried, and evaporated. The reddish yellow residue 
was dissolved in acetone-H2O (3 : 1, 10 mL). After stirred at 40 
o
C for 20 h the mixture was diluted 
with EtOAc (15 mL), washed with H2O (10 mL×3) and brine (10 mL), dried, and evaporated. 
Column chromatography of the residue (EtOAc : hexane = 1 : 1) afforded 34 (77 mg, 29 %) as a 
yellow oil. IR: 3438, 1771cm
-1
; 
1
H NMR: δ = 2.37 (s, 3H), 3.35 (br. s, 1H), 3.91 (s, 3H), 3.93 (s, 3H), 
4.43 (d, J = 2.8 Hz, 1H), 4.99 (br. s, 1H), 6.07 (s, 2H), 7.10 (s, 1H), 7.41 (s, 1H), 7.48 (s, 1H), 7.98 (s, 
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1H); 
13
C NMR: δ = 20.9, 55.3, 56.6, 63.6, 73.7, 86.7, 102.1, 107.5, 110.2, 110.4, 119.3, 121.8, 124.2, 
131.6, 140.3, 144.5, 147.9, 150.0, 153.5, 167.3, 168.3, 171.5; HR(ESI)MS m/z: Calcd for 
C22H19
81
BrNO9: 522.02227; found: 522.02488 
 
6-[2-(3-Bromo-1-methyoxyimino-6,7-methylenedioxy-4-oxo-1,4-dihydronaphthyl)]-4-hydroxy-
3-methoxybenzoic Acid (35) 
A solution of 34 (46 mg, 6.9×10
-2
 mmol) and IBX (39 mg, 1.38×10
-1
 mmol) in DMSO (1mL) was 
stirred at 50 
o
C for 2h, quenched with H2O (5 mL), and extracted with EtOAc (5 mL×3). The 
combined organic solutions were washed with H2O (10 mL) and brine (10 mL), dried, and 
evaporated.  The residue was dissolved in CH2Cl2 (5 mL), stirred at r.t. for 2 h after addition of 
Et3N (19 µL, 1.38×10
-1
 mmol) under ice-cooling, and extracted with solution of 30% aq. Na2CO3 (5 
mL×3). The combined aqueous solutions were acidified with 10% HCl (pH ca 3) and extracted with 
EtOAc (5 mL×3). The combined organic solutions were dried and evaporated. Column 
chromatography of the residue (EtOAc:n-hex = 2:3 ) afforded 35 (36 mg, 99%) as yellow oil of 1:10 
of (1’Z,3’E)- and (1’E,3’E). IR: 1768, 1647, 1609 cm
-1
; 
1
H NMR for major isomer: δ = 2.34 (s, 3H), 
3.94 (s, 3H), 3.95 (s, 3H), 6.13 (s, 1H), 6.16 (s, 1H), 6.94 (s, 1H), 7.70 (s, 1H), 7.76 (s, 1H), 8.32 (s, 
1H); 
13
C NMR for major isomer: δ = 21.0, 56.3, 65.1), 102.8, 107.6, 110.1, 114.6, 124.2, 125.2, 
126.3, 127.4, 133.4, 143.3, 146.6, 149.7, 151.2, 151.3, 152.0, 168.4, 177.3; HR(ESI)MS: m/z calcd 
for C22H17
81
BrNO9: 520.00662; found: 520.00472 
 
Methyl 
6-[2-(3-Bromo-1-methyoxyimino-6,7-methylenedioxy-4-oxo-1,4-dihydronaphthyl)]-4-hydroxy-
3-methoxybenzoate (36) 
A mixture of 35 (19 mg, 3.67×10
-2
 mmol), MeI (5 µL, 7.27×10
-2
 mmol), and K2CO3 (10 mg, 
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7.27×10
-2
 mmol) in DMF (1 mL) was stirred at r.t. for 2 h, quenched with H2O (5 mL), and extracted 
with EtOAc (3 mL×3). The combined organic solutions were washed with saturated solution of 
NaHCO3 in H2O (5 mL) and brine (5 mL), dried, and evaporated.  Column chromatography of the 
yellow residue (hexane : EtOAc = 2 : 3) afforded 36 (13 mg, 65%) as yellow oil of 1:10 of 
(1’Z,3’E)- and (1’E,3’E). IR: 1721, 1648 cm
-1
; 
1
H NMR for major isomer: δ = 2.33 (s, 3H), 3.70 (s, 
3H), 3.95 (s, 3H), 3.96 (s, 3H), 6.12 (s, 2H), 6.95 (s, 1H), 7.66 (s, 1H), 7.77 (s, 1H), 8.34 (s, 1H); 
13
C 
NMR for major isomer: δ = 20.7, 52.5, 56.1, 64.9, 102.4, 107.2, 110.0, 113.7, 124.5, 124.8, 125.8, 
127.3, 132.5), 142.5, 146.4, 149.7, 150.6, 151.2, 151.9, 165.7), 168.3, 177.0; HR(ESI)MS m/z: calcd. 
for C23H19
81
BrNO9: 534.02227; found: 534.01988.  
 
Methyl 
4-Hydroxy-3-methoxy-6-[2-(1-methyoxyimino-6,7-methylenedioxy-4-oxo-1,4-dihydronaphthyl)
]benzoate (10a) 
A mixture of 36 (7 mg, 1.3×10
-3
 mmol), Pd(OAc)2 (0.15 mg, 7×10
-5
 mmol), and Ph3P (0.7 mg, 
2.6×10
-4
 mmol) in n-BuOH (3 mL) was stirred at 100 
o
C for 2 h under nitrogen atmosphere, diluted 
with EtOAc (6 mL), and filtered through Celite pad. The filtrate was washed with H2O (3 mL×2) 
and brine (3 mL), dried, and evaporated. Column chromatography of the residue (SiO2, EtOAc : 
hexane = 1 : 1) afforded 10a (5.1 mg, 93%) as light-yellow solid, mp 89-91 
o
C. IR (ATR): 3437, 
1771 cm
-1
; 
1
H NMR (400 MHz, CDCl3) for (Z)-isomer:  = 3.64 (s, 3H), 3.97 (s, 3H), 4.00 (s, 3H), 
6.12 (s, 2H), 6.49 (s, 1H), 6.91 (s, 1H), 7.49 (s, 1H), 7.70 (s, 1H), 8.35 (s, 1H); 
13
C NMR (100 MHz, 
CDCl3) for (Z)-isomer:  = 52.2, 56.4, 64.5, 102.3, 106.4,  110.2, 112.4, 116.6, 123.1, 124.6, 127.3, 
129.0, 133.2, 146.1, 146.5, 148.7, 149.5, 151.5, 153.4, 167.1, 183.6; HRMS(ESI): m/z calcd for 
C21H17NNaO8: 434.08519; found: 434.08329.  
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General procedure for preparation of compounds 39a-c. 
A mixture of NCbz-protected amino acid (3 eq), Et3N (2 eq), and HATU (3 eq) in DMF (3 mL) was 
stirred at r.t. for 1 h, followed by 10b and HOBt (1 eq) and further stirred for 18 h at rt. The reaction 
was quenched with H2O (5 mL), and extracted with EtOAc (3 mLx3). The combined organic 
solutions were washed with saturated solution of NaHCO3 in H2O (3 mLx 2) and brine (3 mL), dried 
over MgSO4, and evaporated.  Column chromatography of the resulted residue (hexane : EtOAc = 
3 : 2) afforded 39a-c.  
 
39a Methyl 6-[2-(1-methyoxyimino-6,7-methylenedioxy-4-oxo-1,4-dihydronaphthyl)]-2- 
(N-Cbz-gly-O-)-3-methoxybenzoate 
84 % Yield. IR (ATR): 3437, 1771, 1760 cm
-1
; 
1
H NMR (400 MHz, CDCl3) :  = 3.61 (s, 3H), 3.89 
(s, 3H), 4.01 (s, 3H), 4.32 (s, 2H), 5.16 (s, 2H), 5.32 (s, 1H), 6.12 (s, 2H), 6.59 (s, 1H), 7.01 (s, 1H), 
7.25 (s, 3H), 7.38 (s, 2H), 7.70 (s, 1H), 8.35 (s, 1H); 
13
C NMR (100 MHz, CDCl3)  56.3, 64.7, 
102.2, 106.2,  109.8, 113.8, 128.0, 128.1, 128.2, 128.6, 130.0,136.3, 137.8, 145.1, 149.5, 151.4, 
152.0, 163.6, 165.3, 167.8, 183.4; HRMS(ESI): m/z calcd for C31H26N2NaO11: 625.144404; found: 
625.14343. 
 
39b Methyl 
6-[2-(1-methyoxyimino-6,7-methylenedioxy-4-oxo-1,4-dihydronaphthyl)]-2-(N-Cbz-β-ala-O-)3-
methoxybenzoate 
Prepared similarly to compound 39a 
 78 % Yield, IR (ATR): 3437, 1771, 1760 cm
-1
; 
1
H NMR (400 MHz, CDCl3) :  = 2.89 (s, 2H), 3.50 
(s, 3H), 3.66 (s, 2H), 3.89 (s, 3H), 4.01 (s, 3H), 5.12 (s, 2H), 5.72 (s, 1H), 6.12 (s, 2H), 6.60 (s, 1H), 
7.01 (s, 1H), 7.35 (s, 6H), 7.70 (s, 1H), 8.33 (s, 1H); 
13
C NMR (100 MHz, CDCl3)  
56.2, 64.7, 66.7, 102.2, 106.2,  109.8, 113.8, 124.0, 127.6, 128.0, 128.1, 128.4, 128.5, 128.6, 130.0, 
132.1, 136.5, 137.9, 144.9, 149.4, 151.5, 151.8, 156.3, 156.4, 165.5, 169.6, 183.4; HRMS(ESI): m/z 
calcd for C32H28N2NaO11: 639.15758; found: 639.15908. 
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39c Methyl 
6-[2-(1-methyoxyimino-6,7-methylenedioxy-4-oxo-1,4-dihydronaphthyl)]-2-(N-Cbz-γ-butyric 
acid-O-)3-methoxybenzoate 
Prepared similarly to compound 39a 
89 % Yield, IR (ATR): 3437, 1771, 1760 cm
-1
; 
1
H NMR (400 MHz, CDCl3) :  = 2.00 (s, 2H), 2.67 
(m, 2H), 3.36 (s, 2H) 3.50 (s, 3H), 3.88 (s, 3H), 4.01 (s, 3H), 5.10 (s, 2H), 5.18 (s, 1H), 6.12 (s, 2H), 
6.60 (s, 1H), 7.01 (s, 1H), 7.35 (s, 6H), 7.70 (s, 1H), 8.33 (s, 1H); 
13
C NMR (100 MHz, CDCl3) 
 52.2, 56.2, 64.7, 66.7, 68.0, 102.2, 106.2,  109.7, 113.5, 124.0, 
127.7, 127.9, 128.1, 128.2, 128.4, 128.5, 128.6, 130.0, 136.5, 138.4, 144.9, 149.5, 151.4, 151.5, 
152.0, 156.5, 165.5, 170.6, 183.4; HRMS(ESI): m/z calcd for C33H30N2KO11: 669.15103; found: 
669.14867. 
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Chapter 5 
Conclusion 
 Four 2-aryl-1,4-naphthoquinone synthesized were biologically active in vitro 
antitumor  studies.  Compounds (39a-c)-type may be potent drug candidates and their 
potency may be increased with relatively simple structural changes in the 2-aryl group, 
hence aiding to the insight to future optimization of the series. 
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